Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Bradykinesia
NCT04385056Phase 1Unknown
- Sponsor
- IMAC Holdings
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MSCTC-0010 in bradykinesia (3 arms), sponsored by IMAC Holdings. Primary endpoint: Incidence of Serious Adverse Events and Adverse Events at 12 months. Status: unknown.
02
Drugs
MSCTC-0010
03
Conditions
bradykinesia
Beyond the preview
Go deeper on NCT04385056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385056.